Tech Company Financing Transactions

ReCode Therapeutics Funding Round

ReCode Therapeutics, based in Menlo Park, received $80 million from Colt Ventures, OrbiMed and Hunt Technology Ventures.

Transaction Overview

Announced On
3/27/2020
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series A
Investors

Colt Ventures (Lead Investor)

OrbiMed (Lead Investor) (Peter Thompson)

Hunt Technology Ventures

MPM Capital (Ed Hurwitz)

Osage Partners

Vida Ventures (Helen Kim)

Proceeds Purpose
ReCode will use the proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1455 Adams Dr.
Menlo Park, CA 94025
USA
Email Address
Overview
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).
Profile
ReCode Therapeutics LinkedIn Company Profile
Social Media
ReCode Therapeutics Company Twitter Account
Company News
ReCode Therapeutics News
Facebook
ReCode Therapeutics on Facebook
YouTube
ReCode Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Lockhart
  David Lockhart LinkedIn Profile  David Lockhart Twitter Account  David Lockhart News  David Lockhart on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/27/2020: Fast venture capital transaction
Next: 3/27/2020: SutroVax venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary